FibroBiologics, Inc. ( (FBLG) ) has issued an announcement.

Discover the latest on Akero Therapeutics, Inc., a biotech firm focusing on metabolic balance therapies, with a market cap of ...

Yorkville agreed to advance to FibroBiologics the first $15 million available under the SEPA in three equal tranches to be evidenced by convertible promissory notes. The first tranche in the amount of ...

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures ...

Futibatinib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Esophageal Cancer.

Real Betis stadium A new potential anti-cancer target - RUNX2 Luye's new anti-tumor drug clinical trial accepted; China's first compound liposome dru ...

Fibroblast/Astellas Roxadus enters review in the EU Anniversary of the Science and Technology Innovation Board \| Panoramic r ...

Four measures to improve the income level of medical staff Johnson & Johnson Q2 quarterly report released: net profit fell by more than 35%, only the pharmaceutical business achieved growth Fibroblast ...

Guardian F1 live today First-line maintenance treatment for gBRCAm pancreatic cancer! AZ/Merck Lynparza is expected to be approved by the EU soon ...

Peptides, as versatile biological molecules, have garnered significant attention in scientific research due to their ...